Skip to main content

Table 1 Patient characteristics

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Characteristic   %
Age (years)
 Median 63  
 Range 37–77  
Sex
 Male 75 72.1
 Female 29 27.9
ECOG PS
 0 93 89.4
 1 10 9.6
 2 1 1
Location of pancreatic tumor
 Head 27 26
 Body/tail 46 44.2
 Recurrent after resection 31 29.8
Metastatic site
 Liver 72 69.2
 Lung 19 18.3
 Peritoneum 16 15.4
Biliary drainage
 Yes 18 17.3
 No 86 82.7
UGT1A1*6/UGT1A1*28
 Wild/wild 48 46.2
 Wild/heterozygous 13 12.5
 Heterozygous/wild 33 31.7
 Heterozygous/heterozygous 4 3.8
 Homozygous (*6 or *28) 4 3.8
 NA 2 1.9
CEA (ng/mL)
 Median 6.1  
 Range 1.2–10,068  
CA19–9 (IU/mL)
 Median 814.5  
 Range 2–50,000  
Alb (g/dL)
 Median 3.6  
 Range 2.5–4.4  
CRP (mg/dL)
 Median 0.31  
 Range 0.01–8.75  
  1. Alb albumin, CA19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, NA not available, UGT1A1 uridine diphosphate glucuronosyltransferase 1A1